RafaelBejarMDPhD

Hematologic Oncology

Assistant Professor, University of California, San Diego

Dr. Bejar is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
3855 Health Sciences Dr
# MC0820
La Jolla, CA 92093
Phone+1 858-534-5204

Fax+1 858-246-1847

Rafael Bejar, MD, PhD is a practicing hematologist based in La Jolla, CA, with a subspecialty in hematologic oncology. He completed his medical and graduate school education at the University of California San Diego School of Medicine, followed by an internship and residency at University of Chicago and Brigham and Women's Hospital, respectively, followed by a fellowship in Hematology and Medical Oncology at Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer Institute. He is currently the Chief Medical Officer and Senior Vice President at Aptose Biosciences, Inc. and serves as an Associate Professor at UC San Diego Health. Dr. Bejar has extensive experience in hematologic oncology, particularly myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), and has contributed to multiple publications and clinical trials focusing on these areas. Dr. Bejar has served on the NCCN Guidelines Committee for MDS. He is a member of the International Working Group for MDS Molecular Prognosis Committee and the 2022 WHO Classification Committee. He is on the steering committee for the National MDS Study and serves on the Medical & Scientific Advisory Board of the MDS Foundation.

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2006 - 2011
Brigham and Women's HospitalResidency, Internal Medicine, 2004 - 2006
University of ChicagoInternship, Internal Medicine, 2003 - 2004
University of California San Diego School of MedicineClass of 2003

PubMed

Abstracts/Posters

TP53 State Dictates Genome Stability, Clinical Presentation and Outcomes in Myelodysplastic Syndromes
Rafael Bejar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Clonal Cytopenias of Undetermined Significance Are Common in Cytopenic Adults Evaluated for MDS in the National MDS Study
Rafael Bejar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

Wide Variation in Use and Interpretation of Gene Mutation Profiling Panels Among Health Care Providers of Patients with Myelodysplastic Syndromes (MDS): Results of a L...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
DNA Methylation Identifies Genetically and Prognostically Distinct Subtypes of MDS
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Hippo Kinase Inactivation Contributes to Del(20q) Malignancies and Cooperates with JAK2-V617F to Promote Myelofibrosis in Mice
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine TrialsDecember 2nd, 2024
Aptose Reports Results for the Second Quarter 2022August 2nd, 2022
HM43239 Demonstrates Durable Clinical Benefit in Acute Myeloid LeukemiaDecember 13th, 2021
Join now to see all